Krystal Biotech (KRYS) Other financing activities (2023 - 2026)

Krystal Biotech has reported Other financing activities for 4 years, with the latest figure at $15.2 million in Q2 2026.

• Other financing activities for Q2 2026 came in at $15.2 million, up 744.15% year-over-year; the trailing twelve-month figure through Jun 2026 was $41.1 million (up 353.71% YoY), and the FY2025 annual result was $22.7 million, down 30.06% from the prior year.
• Other financing activities climbed to $15.2 million in Q2 2026, from $6.5 million in the prior quarter.
• Over five years, Other financing activities peaked at $25.4 million in Q2 2023 and troughed at $1.5 million in Q1 2025.
• A 4-year average of $8.6 million and a median of $5.1 million in 2025 frame the typical range for Other financing activities.
• The widest annual swing landed in 2025, when Other financing activities plunged 90.84%; it then soared 744.15% in 2026.
• A 4-year view of Other financing activities shows it stood at $2.6 million in 2023, then retreated by 6.94% to $2.4 million in 2024, then soared by 546.17% to $15.7 million in 2025, then retreated by 3.37% to $15.2 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $15.2 million in Q2 2026, $6.5 million in Q1 2026, and $15.7 million in Q4 2025.